These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23023615)

  • 21. Pulmonary arterial hypertension: a review in pharmacotherapy.
    Patel BB; Feng Y; Cheng-Lai A
    Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study.
    Bravo-Marqués R; Becerra-Muñoz V; Espíldora-Hernández F; Recio-Mayoral A;
    Clin Ther; 2024 Jun; 46(6):509-514. PubMed ID: 38762398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
    Dowdall M
    Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
    [No Abstract]   [Full Text] [Related]  

  • 24. Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
    Fleming T; Lindenfeld J; Lipicky R; Armstrong P
    Circulation; 2001 Oct; 104(15):1742. PubMed ID: 11591605
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in prostacyclin therapy for pulmonary arterial hypertension.
    Eells PL
    Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
    [No Abstract]   [Full Text] [Related]  

  • 26. [Drug therapy of primary and secondary pulmonary hypertension].
    Olschewski H
    Herz; 2002 Aug; 27(5):463-7. PubMed ID: 12365287
    [No Abstract]   [Full Text] [Related]  

  • 27. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
    Rich J; Hoeper MM
    Int J Clin Pract Suppl; 2009 Mar; (161):17-8. PubMed ID: 19178601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.
    Waxman AB
    Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828
    [No Abstract]   [Full Text] [Related]  

  • 29. [Bosentan: a new pillar in the treatment of pulmonary hypertension?].
    Matthes J; Groner F
    Dtsch Med Wochenschr; 2006 May; 131(18):1031-4. PubMed ID: 16673229
    [No Abstract]   [Full Text] [Related]  

  • 30. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
    Park J; Song JH; Park DA; Lee JS; Lee SD; Oh YM
    J Korean Med Sci; 2013 Aug; 28(8):1200-6. PubMed ID: 23960448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The SERAPHIN study].
    D'Alto M; Vitulo P
    G Ital Cardiol (Rome); 2015 Jan; 16(1):6-10. PubMed ID: 25689745
    [No Abstract]   [Full Text] [Related]  

  • 33. Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
    Lázaro Salvador M; Escribano Subías P; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):393-394. PubMed ID: 30910272
    [No Abstract]   [Full Text] [Related]  

  • 34. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition.
    Tapper EB; Knowles D; Heffron T; Lawrence EC; Csete M
    Transplant Proc; 2009 Jun; 41(5):1969-71. PubMed ID: 19545770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary hypertension].
    Olschewski H; Ghofrani A; Wiedemann R; Rose F; Enke B; Gessler T; Voswinckel R; Kohstall M; Grimminger F; Seeger W
    Internist (Berl); 2002 Dec; 43(12):1498, 1501-9. PubMed ID: 12607389
    [No Abstract]   [Full Text] [Related]  

  • 37. Recruitment of pulmonary hypertension patients for PATENT trial with Riociguat [corrected] completed Sub-Saharan pulmonary hypertension study launched.
    Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):120. PubMed ID: 22447482
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacological and clinical profile of treprostinil (TREPROST® for injection)].
    Saito R; Ohmori Y
    Nihon Yakurigaku Zasshi; 2016 Jan; 147(1):56-62. PubMed ID: 26753860
    [No Abstract]   [Full Text] [Related]  

  • 39. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bosentan in pulmonary hypertension].
    Heinzl S
    Med Monatsschr Pharm; 2002 Mar; 25(3):74-6. PubMed ID: 11925765
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.